✦ LIBER ✦

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial

✍ Scribed by Florence Wong; Andres T. Blei; Laurence M. Blendis; Paul J. Thuluvath

Book ID: 111722090
Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 151 KB
Volume: 37
Category: Article
ISSN: 0270-9139
DOI: 10.1053/jhep.2003.50021

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Double-Blind, Placebo-Controlled, Multic

Double-Blind, Placebo-Controlled, Multicenter Trial of a Vasopressin V2-Receptor Antagonist in Patients with Schizophrenia and Hyponatremia

✍ Richard C. Josiassen; Morris Goldman; Meera Jessani; Rita A. Shaughnessy; Ala Al 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

Acute Hemodynamic Effects of Tolvaptan,

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial

✍ James E. Udelson; Cesare Orlandi; John Ouyang; Holly Krasa; Christopher A. Zimme 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 561 KB

Acute Hemodynamic Effects of Tolvaptan,

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial

✍ James E. Udelson; Cesare Orlandi; John Ouyang; Holly Krasa; Christopher A. Zimme 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Initial experience with an intravenous P

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

✍ Adam B. Greenbaum; Cindy L. Grines; John A. Bittl; Richard C. Becker; Dean J. Ke 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 275 KB

Clinical trial: short-term effects of co

Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study

✍ P. GINÈS; F. WONG; H. WATSON; R. TERG; R. BRUHA; J.-P. ZARSKI; F. DUDLEY; FOR TH 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB